Amphastar Pharmaceuticals (AMPH) Receivables (2016 - 2026)
Amphastar Pharmaceuticals has reported Receivables over the past 13 years, most recently at $143.6 million for Q4 2025.
- For Q4 2025, Receivables rose 5.33% year-over-year to $143.6 million; the TTM value through Dec 2025 reached $143.6 million, up 5.33%, while the annual FY2025 figure was $143.6 million, 5.33% up from the prior year.
- Receivables for Q4 2025 was $143.6 million at Amphastar Pharmaceuticals, down from $147.3 million in the prior quarter.
- Over five years, Receivables peaked at $147.3 million in Q3 2025 and troughed at $67.9 million in Q2 2021.
- A 5-year average of $109.0 million and a median of $109.8 million in 2023 define the central range for Receivables.
- Biggest five-year swings in Receivables: fell 6.12% in 2022 and later skyrocketed 53.93% in 2023.
- Year by year, Receivables stood at $78.8 million in 2021, then rose by 12.69% to $88.8 million in 2022, then increased by 29.43% to $114.9 million in 2023, then increased by 18.57% to $136.3 million in 2024, then grew by 5.33% to $143.6 million in 2025.
- Business Quant data shows Receivables for AMPH at $143.6 million in Q4 2025, $147.3 million in Q3 2025, and $133.0 million in Q2 2025.